MXPA04005561A - Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. - Google Patents

Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.

Info

Publication number
MXPA04005561A
MXPA04005561A MXPA04005561A MXPA04005561A MXPA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A MX PA04005561 A MXPA04005561 A MX PA04005561A
Authority
MX
Mexico
Prior art keywords
pyridazine
pyridine derivatives
combination therapies
angiogenesis combination
angiogenesis
Prior art date
Application number
MXPA04005561A
Other languages
English (en)
Inventor
J Elting James
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MXPA04005561A publication Critical patent/MXPA04005561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invencion se relaciona generalmente con el uso de ciertos derivados de piridazina o piridina fundidos o no fundidos substituidos, que son inhibidores de KDR en combinacion con otros agentes quimioterapeuticos para uso en el tratamiento de enfermedades asociadas con angiogenesis anormal y/o hipermeabilidad y/o enfermedades hiperproliferativas, tales como cancer.
MXPA04005561A 2001-12-21 2002-12-20 Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. MXPA04005561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34429401P 2001-12-21 2001-12-21
PCT/US2002/041145 WO2003059354A2 (en) 2001-12-21 2002-12-20 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives

Publications (1)

Publication Number Publication Date
MXPA04005561A true MXPA04005561A (es) 2004-12-06

Family

ID=23349902

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005561A MXPA04005561A (es) 2001-12-21 2002-12-20 Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.

Country Status (7)

Country Link
US (1) US20050019424A1 (es)
EP (1) EP1467736A2 (es)
JP (1) JP2006503796A (es)
AU (1) AU2002364102A1 (es)
CA (1) CA2471314A1 (es)
MX (1) MXPA04005561A (es)
WO (1) WO2003059354A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
JP2006514991A (ja) * 2002-12-27 2006-05-18 シエーリング アクチエンゲゼルシャフト 新規医薬組合せ
CA2518530A1 (en) * 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
WO2010065825A2 (en) 2008-12-05 2010-06-10 Abbott Laboratories Kinase inhibitors with improved cyp safety profile
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
CA3026784A1 (en) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic pyrazine derivatives useful as shp2 inhibitors
KR20210130254A (ko) 2017-03-23 2021-10-29 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
AR119493A1 (es) * 2019-07-29 2021-12-22 Servier Lab Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
US6689883B1 (en) * 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität

Also Published As

Publication number Publication date
US20050019424A1 (en) 2005-01-27
WO2003059354A3 (en) 2003-11-13
CA2471314A1 (en) 2003-07-24
AU2002364102A1 (en) 2003-07-30
JP2006503796A (ja) 2006-02-02
AU2002364102A8 (en) 2003-07-30
WO2003059354A2 (en) 2003-07-24
EP1467736A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
MXPA04005561A (es) Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HK1080466A1 (zh) 用於治療過度增生疾病的稠合三環雜環
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
TW200504053A (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA04004064A (es) Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
IL146482A (en) Tek antagonists
HK1046912A1 (en) Substituted sapogenins and their use
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
IN228043B (es)
AP2004002995A0 (en) Combination therapy for the treatment of cancer
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
WO2003090680A3 (en) Novel phenyl derivatives as inducers of apoptosis
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
ATE360062T1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
AU6301398A (en) Arrestable therapeutic viral agent
TW200505440A (en) Novel fused triazolones and the uses thereof
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом